Correspondence 0001193125-23-279958 from Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc.
Date: Nov. 17, 2023 · CIK: 0001636282 · Accession: 0001193125-23-279958
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273769
Letter
Re: Aeglea BioTherapeutics, Inc.
November 17, 2023
VIA EDGAR AND EMAIL
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Laura Crotty and Dillon Hagius
Registration Statement on Form S-1
Filed August 7, 2023
File No. 333-273769
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company be accelerated to 4:01 p.m., Eastern Standard Time, on November 20, 2023 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631.
Very truly yours,
AEGLEA BIOTHERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP November 17, 2023 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Laura Crotty and Dillon Hagius Re: Aeglea BioTherapeutics, Inc. Registration Statement on Form S-1 Filed August 7, 2023 File No. 333-273769 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company be accelerated to 4:01 p.m., Eastern Standard Time, on November 20, 2023 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631. Very truly yours, AEGLEA BIOTHERAPEUTICS, INC. By: /s/ Cameron Turtle Name: Cameron Turtle Title: Chief Operating Officer cc: Scott Burrows, Aeglea BioTherapeutics, Inc. Heidy King-Jones, Aeglea BioTherapeutics, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP